Free scoping read. A written assessment of your manuscript in two business days, at no cost.

Start one

Call for papersPharmacology and drug development

Call for Papers: Molecular Insights into Preclinical and Clinical Pharmacology (Current Issues in Molecular Biology)

Current Issues in Molecular Biology is running a Special Issue in its Molecular Pharmacology section on molecular mechanisms underpinning preclinical and clinical pharmacology, also listed in the IJMS Molecular Pharmacology section. This guide outlines topic areas consistent with that scope, fit checks, contribution types editors tend to value and practical steps for submitting before the 31 March 2027 deadline.

Pubrica InsightsEditorial team, reviewed by a subject specialist
Deadline
31 March 2027
Last checked
10 November 2026
Reading time
5 min
Sources
1
Submit through the official call

Key dates

Manuscript deadline
31 March 2027
Details last checked
10 November 2026
Open the official call

About the journal

Journal
Current Issues in Molecular Biology
Publisher
MDPI
Call type
Call for papers
Scope
Special Issue in the Molecular Pharmacology section on molecular mechanisms underpinning preclinical and clinical pharmacology (also listed in the IJMS Molecular Pharmacology section).
Guest editors
Listed on the official collection page
Access and fees
Open access; an article processing charge normally applies on acceptance
Originality
Original work, not under review elsewhere; confirm on the official page

Topics consistent with the call

  • Molecular mechanisms of drug action at receptors, enzymes and signalling pathways
  • Preclinical models for evaluating efficacy, toxicity and mechanism of new compounds
  • Pharmacogenomic and molecular determinants of clinical drug response
  • Mechanisms of drug resistance and strategies to overcome it
  • Drug repurposing supported by molecular and computational evidence
  • Translational studies linking preclinical findings with clinical pharmacology

Based on the published scope; the full list of themes is on the official call page.

Is your work a fit? Check before you write

  1. Address molecular mechanisms relevant to preclinical or clinical pharmacology.
  2. Support mechanistic claims with appropriate controls, replication and orthogonal methods.
  3. Report compounds, doses, models and statistical methods in full.
  4. Confirm accepted article types and article processing charges on the official call page.
  5. Submit a complete, co-author-approved manuscript before 31 March 2027.

Why This Call Is a Priority Now

Understanding how drugs act at the molecular level underpins the discovery of new treatments, the interpretation of variable patient responses and the reduction of adverse effects. Advances in omics, structural biology and computational methods have made it easier to connect preclinical mechanism with clinical outcome. A Special Issue that spans preclinical and clinical pharmacology allows authors to present mechanistic work alongside translational studies for a readership interested in molecular pharmacology.

Who Should Submit

Academic backgrounds

  • Pharmacology and toxicology
  • Molecular and cell biology
  • Medicinal chemistry
  • Clinical pharmacology
  • Computational biology

Institutions and sectors

  • Universities and pharmacy schools
  • Pharmaceutical and biotechnology companies
  • Contract research organisations
  • Academic hospitals and translational research centres

Article types commonly published in Current Issues in Molecular Biology

  • See the journal’s article types

What the Editors Typically Value

  1. Mechanistic studies that clearly identify molecular targets and pathways of drug action.
  2. Translational work connecting preclinical mechanisms with clinical response or toxicity.
  3. Research on mechanisms of resistance that suggests rational combination or alternative strategies.
  4. Integrative approaches combining experimental and computational evidence for drug repurposing.

Paper Ideas You Could Develop

Mechanism of a repurposed drugA study combining molecular docking, cell-based assays and animal models to characterise the mechanism of an approved drug in a new indication.
Pharmacogenomics of drug toxicityAn investigation of genetic variants in drug-metabolising enzymes associated with toxicity in a clinical cohort, supported by functional assays.
Resistance pathways in cancer therapyA preclinical study identifying signalling changes associated with acquired resistance to a targeted therapy.

Your Plan to the Deadline

A suggested schedule working back from 31 March 2027. Adjust it to the stage your work has reached.

  1. By 14 Feb 2027

    Open the official collection page and the Current Issues in Molecular Biology submission guidelines; confirm the scope, article types and guest editors.

  2. By 28 Feb 2027

    Write a one-paragraph statement of your research question, design and the contribution your paper makes to the collection.

  3. By 10 Mar 2027

    Complete the analysis and agree the key findings, figures and tables with your co-authors.

  4. By 21 Mar 2027

    Draft the full manuscript to the Current Issues in Molecular Biology article type and the relevant reporting guideline.

  5. By 26 Mar 2027

    Circulate the draft to co-authors and an independent reader; revise for clarity, accuracy and completeness.

  6. By 29 Mar 2027

    Complete final checks: formatting, references, declarations, data availability statement and cover letter.

  7. By 31 Mar 2027

    Submit through the journal’s online system, selecting the collection, after re-checking the official call page.

What you gain from publishing here

  • Publication in Current Issues in Molecular Biology, reaching readers working on this topic.
  • A themed collection that groups your paper with related work.
  • Editorial and peer feedback that can strengthen the work, whatever the decision.
  • A peer-reviewed output for your CV, thesis or grant reporting.

What happens after you submit

  1. Submission: upload through the Current Issues in Molecular Biology online system and select the collection.
  2. Editorial screening: the editors check fit with the collection; papers outside its scope may be returned without review.
  3. Peer review: suitable papers are sent to reviewers under the journal’s review model.
  4. Revision and decision: respond to each reviewer comment and keep a record of the changes.
  5. Production: accepted papers move to proofs and open access publication, with the article processing charge set out by the publisher.

What the Collection Is Looking For

The Special Issue seeks research on the molecular mechanisms that underpin preclinical and clinical pharmacology. Consistent with the journal’s focus on molecular biology, it is likely to welcome original research and reviews on drug targets, signalling, resistance, pharmacogenomics and translational pharmacology. Rigorous mechanistic evidence and clear relevance to therapy will strengthen a submission. Authors should confirm accepted article types, the relationship with the IJMS listing and article processing charges on the official call page.

Read the call itselfThis guide summarises the call. Open the official collection page before you plan a submission, and record the date you checked it and the guest editors listed.Open the official call

Expert help

How Pubrica Can Help With This Submission

Pubrica’s subject specialists can review, write, edit, format and prepare your manuscript for this call, planned back from the deadline. You remain the author of your work.

Pre-submission peer reviewAn expert review of the manuscript against the call and the journal’s requirements. Manuscript editingSubject-specialist editing for clarity, accuracy and consistency. Journal formattingFormatting of the manuscript, references, figures and tables to the journal’s guidelines. BiostatisticsStatistical analysis and review of results. Cover letterA cover letter that explains how the manuscript fits the call. Journal submissionPreparation of submission files and completion of the online submission.
Go to the official call

FAQs

Questions Authors Ask

The published deadline is 31 March 2027. Collections can close early or be extended, so confirm the date on the official call page before you plan your submission.

The guest editors are listed on the official collection page. Check their research interests, as they help to judge whether your manuscript fits the collection.

Computational work may fit, but mechanistic claims are generally stronger when supported by experimental validation. Authors should check the official call page and the journal’s guidelines on computational studies before submitting.

Access model: Open access. Check the journal’s fees page for any article processing charge before you submit.

Sources

  1. Current Issues in Molecular Biology. (2026). Molecular Insights into Preclinical and Clinical Pharmacology [Collection call for papers]. MDPI. Retrieved 10 November 2026, from https://www.mdpi.com/journal/cimb/special_issues/1YB8I284AZ

How to cite this page

Pubrica Insights. (2026). Call for Papers: Molecular Insights into Preclinical and Clinical Pharmacology (Current Issues in Molecular Biology). Pubrica. https://pubrica.com/insights/calls-and-conferences/molecular-insights-into-preclinical-and-clinical-pharmacology/

  • Molecular pharmacology
  • Drug mechanisms
  • Preclinical research
  • Clinical pharmacology
  • Pharmacogenomics

Other Open Calls

Closes 31 December 2026Climate-Resilient Health Systems and Planetary HealthPLOS Global Public Health Closes 31 December 2026Resilience in the Aftermath of Crises: Health Systems, Communities, and Global Health EquityGlobal Health Action Closes 31 December 2026Formal (Paid) Home-Based Health CareMedical Care Research and Review

All calls and conferencesPre-submission peer reviewAll Insights

Molecular Insights into Preclinical and Clinical Pharmacology (Current Issues in Molecular Biology)Deadline 31 March 2027

Official call
Get a free quote

Regulations

Check your project against this rule

  1. 1Your work
  2. 2Your details
  3. 3Send
What do you need?

Material you send is held under signed confidentiality, with access limited to the assigned team and encrypted transfer. It is not used to train anything and is not passed to third-party tools. Ask for the agreement before you send anything you would rather cover first.